More recently, small molecule inhibitors targeting mutant IDH proteins (IDH1 and IDH2) found in an additional 15–20% of AML patients have entered clinical use (Pollyea et al, 2019; Roboz et al, 2020). This evidence concerns the gene IDH1 and acute myeloid leukemia.